Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2007-12-20
2010-11-09
Zucker, Paul A (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C560S042000
Reexamination Certificate
active
07829592
ABSTRACT:
Catechol protected levodopa diester prodrugs pharmaceutical, compositions comprising catechol protected levodopa diester prodrugs, and methods of using such prodrugs and pharmaceutical compositions for treating diseases such as Parkinson's disease are provided.
REFERENCES:
patent: 3811444 (1974-05-01), Heller et al.
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 3962414 (1976-06-01), Michaels
patent: 3992518 (1976-11-01), Chien et al.
patent: 4038411 (1977-07-01), Saari
patent: 4066747 (1978-01-01), Capozza
patent: 4070347 (1978-01-01), Schmitt
patent: 4079038 (1978-03-01), Choi et al.
patent: 4083949 (1978-04-01), Benedikt
patent: 4093709 (1978-06-01), Choi et al.
patent: 4134991 (1979-01-01), Wermuth et al.
patent: 4180509 (1979-12-01), Metcalf et al.
patent: 4311706 (1982-01-01), Bodor et al.
patent: 4663349 (1987-05-01), Repta
patent: 4771073 (1988-09-01), Repta
patent: 4826875 (1989-05-01), Chiesi
patent: 4873263 (1989-10-01), Repta
patent: 4914222 (1990-04-01), Budavari et al.
patent: 4966915 (1990-10-01), Tsuchiya et al.
patent: 4983400 (1991-01-01), Dempski et al.
patent: 5017607 (1991-05-01), Chiesi
patent: 5057321 (1991-10-01), Edgren et al.
patent: 5073641 (1991-12-01), Bundgaard et al.
patent: 5128145 (1992-07-01), Edgren et al.
patent: 5133974 (1992-07-01), Paradissis et al.
patent: 5190763 (1993-03-01), Edgren et al.
patent: 5283352 (1994-02-01), Backstrom et al.
patent: 5332576 (1994-07-01), Mantelle
patent: 5462933 (1995-10-01), Kramer et al.
patent: 5607969 (1997-03-01), Milman et al.
patent: 5698155 (1997-12-01), Grosswald et al.
patent: 5827819 (1998-10-01), Yatvin et al.
patent: 5840756 (1998-11-01), Cohen et al.
patent: 6696600 (2004-02-01), Frenkel et al.
patent: 7101912 (2006-09-01), Xiang et al.
patent: 7323585 (2008-01-01), Xiang et al.
patent: 7342131 (2008-03-01), Xiang et al.
patent: 7534813 (2009-05-01), Xiang et al.
patent: 7563821 (2009-07-01), Xiang et al.
patent: 2002/0099041 (2002-07-01), Gallop et al.
patent: 2003/0152628 (2003-08-01), Licht et al.
patent: 2003/0158254 (2003-08-01), Zerangue et al.
patent: 2005/0209181 (2005-09-01), Akil et al.
patent: 2005/0282891 (2005-12-01), Xiang et al.
patent: 2006/0020028 (2006-01-01), Xiang et al.
patent: 2007/0225366 (2007-09-01), Xiang et al.
patent: 2008/0070984 (2008-03-01), Tran et al.
patent: 2008/0103200 (2008-05-01), Xiang et al.
patent: 2008/0132570 (2008-06-01), Xiang et al.
patent: 2008/0171789 (2008-07-01), Xiang et al.
patent: 2008/0214663 (2008-09-01), Xiang et al.
patent: 2009/0137834 (2009-05-01), Xiang et al.
patent: 2009/0156679 (2009-06-01), Xiang et al.
patent: 2 607 198 (2006-11-01), None
patent: 10 2005 022 276 (2006-11-01), None
patent: 0309827 (1989-04-01), None
patent: 58024547 (1983-02-01), None
patent: WO 86/04579 (1986-08-01), None
patent: WO 88/01615 (1988-03-01), None
patent: WO 01/68065 (2001-09-01), None
patent: WO 02/28882 (2002-04-01), None
patent: WO 2005/121069 (2005-12-01), None
patent: WO 2005/121070 (2005-12-01), None
patent: WO 2007/067495 (2007-06-01), None
patent: WO 2007/087256 (2007-08-01), None
Alpert and Friedhoff, Paradoxical reaction to L-dopa in schizophrenic patients,Am J Psychiatry1978, 135(11), 1329-1332.
Bonelli and Wenning, Pharmacological Management of Huntington's disease: an evidence-based review,Current Pharmaceutical Design2006, 12(21), 2701-2720.
Bruno and Bruno, Effects of L-dopa on pharmacological parkinsonism,Acta Psychiatr Scand1966, 4(3), 264-271.
Buchanan et al., Double blind trial of L-dopa in chronic schizophrenia,Aust N Z J Psychiatry1975, 9(4), 269-271.
Conti et al., Levodopa for idiopathic restless legs syndrome: evidence-based review,Mot Disord2007, 22(13), 1943-1951.
Cools, Dopaminergic modulation of cognitive function-implications for L-dopa treatment in Parkinson's disease,Neuroscience Biobehavioral Rev2006, 30, 1-23.
Cooper et al., L-dopa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease,J. Pharm. Pharmacol.1987, 39, 627-635.
Ebadi and Srinivasan, Pathogenesis, prevention and treatment of neuroleptic-induced movement disorders,Pharmacological Reviews1995, 47(4), 575-604.
Fix et al., Short-chain alkyl esters of L-dopa as prodrugs for rectal absorption,Pharm. Res.1989, 6(6), 501-505.
Fix et al., A comparison of oral and rectal absorption of L-dopa esters in rats and mice,Pharm. Res.1990, 7(4), 384-387.
Floel et al., Dopaminergic effects on encoding of a motor memory in chronic stroke,Neurology2005, 65(3), 472-474.
Floel et al., Levodopa increases memory encoding and dopamine release in the striatum in the elderly,Neurobiology of Aging2006, PMID 17098331.
Garzon-Aburbeh et al., A lymphotropic prodrug of L-dopa: synthesis, pharmacological properties, and pharmacokinetic behavior of 1,3-dihexadecanoyl-2-[(S)-2-amino-3-(3,4-dihydroxyphenyl)propanoyl]propane-1,2,3-triol,J Med Chem1986, 29(5), 687-691.
Gerlach and Luhdorf, The effect of L-dopa on young patients with simple schizophrenia, treated with neuroleptic drugs,Psychopharmacologia1975, 44(1), 105-110.
Hogl et al., Increased daytime sleepiness in Parkinson's disease: a questionnaire survey,Movement Disorders2003, 18(3), 319-323.
Inanaga et al., Double-blind controlled study of L-dopa therapy in schizophrenia,Folia Psychiatr Neurol Jpn1975, 29(2), 123-143.
Jankovic, Treatment of dystonia,Lancet Neurol2006, 5(10), 864-872.
Jaskiw and Popli, A meta-analysis of the response to chronic L-dopa in patients with schizophrenia: therapeutic and heuristic implications,Psychopharmacology2004, 171, 365-374.
Juncos et al., Levodopa methyl ester treatment of Parkinson's disease,Neurology1987, 37(7), 1242-1245.
Kay and Opler, L-dopa in the treatment of negative schizophrenic symptoms: a single-subject experimental study,Int'l J Psychiatry Med1985-86, 15(3), 293-298.
Knecht et al., Levodopa: faster and better word learning in normal humans,Ann. Neurol2004, 56(1), 20-26.
Kulisevsky, Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease,Drugs Aging2000, 16(5), 365-379.
Marrel et al., L-dopa esters as potential prodrugs,Eur J Med Chem—Chim Ther1985, 20(5), 459-465.
Ondo and Jankovic, Restless legs syndrome: clinicoetiologic correlates,Neurology1996, 47(6), 1435-1441.
O'Suilleabhain and Dewey, Contributions of dopaminergic drugs and disease severity to daytime sleepiness in Parkinson disease,Arch Neurol2002, 59(6), 986-989.
Paus et al., Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease,Movement Disorders2003, 18(6), 659-667.
Rascol and Fabre, Dyskinesia: L-dopa-induced and tardive dyskinesia,Clinical Neuropharmacology2001, 24(6), 313-323.
Scheidtmann et al., Effect of levodopa in combination with physiotherapy on functional motor recovery after stroke: a prospective, randomized, double-blind study,Lancet2001, 358(9284), 787-790.
Schneider et al., Familial dopa-responsive cervical dystonia,Neurology2006, 66(4), 599-601.
Silber, Sleep disorders,Neurologic Clin2001, 19(1), 173-186.
Soares and McGrath, The treatment of tardive dyskinesia—a systematic review and meta-analysis,Schizophr Res1999, 39(1), 1-16.
Von Scheele, Levodopa in restless legs,Lancet1986, 2(8504), 426-427.
Bai, pGlu-L-Dopa-Pro: A Tripeptide Prodrug Targeting the Intestinal Peptide Transporter for Absorption and Tissue Enzymes for Conversion.Pharm. Res.1995, 12(7), 1101-1104.
Betarbet et al.,Bioessays2002, 24(4), 308-18.
Berg et al., Pharmaceutical Salts,J. Pharm. Sci.vol. 66, No. 1, Jan. 1977, 19 pages.
Bodor et al., Improved Delivery through Biological Membranes. 4. Prodrugs of L-Dopa.J. Med. Chem.1977, 20(11):1435-1445.
Boivin and Montplaisir, The effects of L-dopa on excessive daytime sleepiness in narcolepsy.Neurology1991, 41:1267-1269.
Cho et al.,Biochem. Biophys. Res. Commun2006, 341, 6-12.
Coleman et al., “A practical guide to polymer miscibility,”Polymer1990, 31, 1187-1203.
Di Stefano et al., Dimeric L-Dopa Derivatives as Potential Prodrugs.Bioorganic&Medicinal Chem. Lett. 11:1085-1088 (2
Nguyen Mark Q.
Xiang Jia-Ning
Yao Fenmei
Zhou Cindy X.
Finnegan Henderson Farabow Garrett & Dunner LLP
XenoPort, Inc.
Zucker Paul A
LandOfFree
Catechol protected levodopa diester prodrugs, compositions,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Catechol protected levodopa diester prodrugs, compositions,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Catechol protected levodopa diester prodrugs, compositions,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4192177